Gilead's Truvada May Cut HIV Infection Risk, FDA Says
In two separate trials, Truvada's combination of tenofovir and emtricitabine taken as a pre-exposure prophylaxis greatly decreased rates of infection in individuals with HIV-infected sexual partners, according to the report.
The FDA's Antiviral Drugs Advisory Committee on Friday will consider Gilead's request to sell Truvada as a preventive treatment, which has been granted priority...
Already a subscriber? Click here to login